Edition:
India

Melinta Therapeutics Q4 Loss Per Share $3.94


Thursday, 14 Mar 2019 

Melinta Therapeutics Inc ::MELINTA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $3.94.Q4 EARNINGS PER SHARE ESTIMATE $-4.33 -- REFINITIV IBES DATA.Q4 REVENUE $96.4 MILLION.Q4 REVENUE ESTIMATE $16.9 MILLION -- REFINITIV IBES DATA.SEES 2019 NET PRODUCT SALES OF APPROXIMATELY $65 MILLION.NET PRODUCT SALES OF $14.6 MILLION FOR Q4 OF 2018.SEES 2019 GROSS MARGIN OF APPROXIMATELY 55%, INCLUDING INTANGIBLE ASSETS AMORTIZATION.SEES 2019 OPERATING EXPENSES OF APPROXIMATELY $140 MILLION. 

Company Quote

4.28
 --
22 Apr 2019